Compare PepsiCo, Inc. (PEP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Viatris Inc — how do they compare? PepsiCo, Inc. trades at $125.97 (market cap $174.89B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: PepsiCo, Inc. is far larger — about 8.7× Viatris Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.61%). Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Viatris Inc for 57 Days on average.
| PEP | VTRS | |
|---|---|---|
Market Cap | $174.89B | $20.03B |
Volume | 23,968,864 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $18.27 |
52-Week Low | $123.64 | $9.74 |
Typical Hold Time | 107 Days | 57 Days |
Enterprise Value | $215.61B | $32.15B |
Dividend Yield | 4.61% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $128.88, up 4.24% today, with a bearish technical signal but strong fundamentals including a 16.14 P/E ratio and 51.59% ROE. Recent quarters show consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding expectations. The company maintains robust cash flow, with 2025 operating cash flow of $12.09 billion, and announced a $1.48 dividend for H2-2026. News highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: analyst consensus targets $146.77 (14% upside) with a 'Hold' bias, but technicals suggest near-term pressure. Risks include competitive pricing pressures and debt levels, while opportunities lie in margin recovery and North American turnaround efforts. The stock offers value with a reasonable valuation and dividend yield, but requires monitoring of volume trends post-price adjustments.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
